Menu
GWAS Study

Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia.

Ware JS, Wain LV, Channavajjhala SK et al.

28783044 PubMed ID
GWAS Study Type
3153 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

WJ
Ware JS
WL
Wain LV
CS
Channavajjhala SK
JV
Jackson VE
EE
Edwards E
LR
Lu R
SK
Siew K
JW
Jia W
SN
Shrine N
KS
Kinnear S
JM
Jalland M
HA
Henry AP
CJ
Clayton J
OK
O'Shaughnessy KM
TM
Tobin MD
SV
Schuster VL
CS
Cook S
HI
Hall IP
GM
Glover M
Chapter II

Abstract

Summary of the research findings

Thiazide diuretics are among the most widely used treatments for hypertension, but thiazide-induced hyponatremia (TIH), a clinically significant adverse effect, is poorly understood. Here, we have studied the phenotypic and genetic characteristics of patients hospitalized with TIH. In a cohort of 109 TIH patients, those with severe TIH displayed an extended phenotype of intravascular volume expansion, increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of serum chloride, magnesium, zinc, and antidiuretic hormone. GWAS in a separate cohort of 48 TIH patients and 2,922 controls from the 1958 British birth cohort identified an additional 14 regions associated with TIH. We identified a suggestive association with a variant in SLCO2A1, which encodes a prostaglandin transporter in the distal nephron. Resequencing of SLCO2A1 revealed a nonsynonymous variant, rs34550074 (p.A396T), and association with this SNP was replicated in a second cohort of TIH cases. TIH patients with the p.A396T variant demonstrated increased urinary excretion of prostaglandin E2 and metabolites. Moreover, the SLCO2A1 phospho-mimic p.A396E showed loss of transporter function in vitro. These findings indicate that the phenotype of TIH involves a more extensive metabolic derangement than previously recognized. We propose one mechanism underlying TIH development in a subgroup of patients in which SLCO2A1 regulation is altered.

48 European ancestry cases, 2,905 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

3153
Total Participants
GWAS
Study Type
Yes
Replicated
94 European ancestry cases, 106 European ancestry controls
Replication Participants
European
Ancestry
U.K.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.